The Future of DDR-Targeted Oncology Starts Here!

The 9th DDR Inhibitors Summit returns to Boston in 2026 as the leading industry meeting dedicated to driving the next generation of DNA Damage Response (DDR)-targeted therapies beyond PARP. Uniting experts from biopharma, biotech, and academia, this is the must-attend event for those pushing the boundaries of synthetic lethality and precision oncology.

As clinical momentum grows for novel DDR targets such as ATR, CHK1/2, WEE1, and DNA-PK, this forum delivers a front-row seat to the latest breakthroughs in biomarker-driven discovery, combination strategies, and resistance-mitigation approaches - helping you advance safer, more effective, and longer-lasting cancer therapies.

What You’ll Gain

Benchmark your pipeline against leading programs advancing ATR, ATM, DNA-PK, and WEE1 inhibitors
Gain actionable translational insights to optimize target validation, patient selection, and trial design
Discover cutting-edge biomarker innovations enabling synthetic lethality beyond PARP
Learn from those shaping the clinical landscape and explore combination strategies transforming oncology care

Featuring Insights From

Hear exclusive updates from leaders and innovators across the DDR field, including representatives from:
Artios Pharma, AstraZeneca, Merck, Eli Lilly, IDEAYA Biosciences, Repare Therapeutics, and more.

Plus, explore early-stage innovation and translational research from pioneering biotech and academic teams redefining how DDR modulation can unlock therapeutic potential across tumor types.

Why Attend?

3 days of data-driven discussion spanning discovery through to clinical development
30+ expert speakers delivering cutting-edge research and strategic insights
12+ hours of networking with DDR innovators, investors, and strategic partners
Dedicated Biomarker Focus Day exploring precision patient stratification
Case studies, panel debates, and poster sessions designed to foster collaboration and spark new partnerships

Whether you’re advancing a first-in-class inhibitor, optimizing translational strategy, or exploring synergistic combinations, the DDR Inhibitors Summit is your gateway to connecting with the brightest minds and most influential players in DDR-targeted oncology.

Don’t miss the world’s only dedicated meeting bringing the full DDR community together to define the future of targeted cancer therapy.

Register your place today: https://ter.li/eqeopo